Oncolytic adenoviral infection of chordoma achieves treatment efficacy associated with immunologic response and tumor microenvironmental alteration.

Saved in:
Bibliographic Details
Title: Oncolytic adenoviral infection of chordoma achieves treatment efficacy associated with immunologic response and tumor microenvironmental alteration.
Authors: Wu X; Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ledbetter D; Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Tsai JW; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Singh S; Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Gumin J; Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Fan X; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Gillard AG; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Shin DH; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Jiang H; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Zhao B; Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ingram D; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Akdemir K; Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Conley AP; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Lazar AJ; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Raza S; Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., North R; Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Tatsui C; Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Lang FF; Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Wang WL; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Rhines LD; Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Gomez-Manzano C; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Fueyo J; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Alvarez-Breckenridge C; Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Source: Neuro-oncology [Neuro Oncol] 2026 Jun 01; Vol. 28 (6), pp. 1458-1473.
Publication Type: Journal Article
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication Model: Print Cited Medium: Internet ISSN: 1523-5866 (Electronic) Linking ISSN: 15228517 NLM ISO Abbreviation: Neuro Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1523-5866
DOI:10.1093/neuonc/noag045